Drug Trial Radar · NCT06672068
A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC
Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Feb 20, 2025
Primary completion
Dec 1, 2027
Study completion Dec 1, 2028
Sponsor
- Lead sponsor
- TYK Medicines, IncIndustry
- Sponsor type
- Industry
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was a parallel, randomized, multicenter phase II clinical trial to evaluate the efficacy and safety of TY-9591 combined with platinum-based chemotherapy as first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR sensitive mutations.
Conditions
- NSCLC
Interventions
TY-9591 80mg QD+pemetrexed+Cisplatin/CarboplatinDrug
TY-9591 80mg QD+pemetrexed 500mg/m²(D1,Q3w)+Carboplatin AUC5/ Cisplatin 75mg/m²(D1,Q3w\*4 cycles)
TY-9591 160mg QD+pemetrexed+Cisplatin/CarboplatinDrug
TY-9591 160mg QD+pemetrexed 500mg/m²(D1,Q3w)+Carboplatin AUC5/ Cisplatin 75mg/m²(D1,Q3w\*4 cycles)
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: Up to 33 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.